However, there was a tendency towards a higher ORR (87.5% vs 55.6%), longer PFS (median 12.0 vs 7.0 months), and longer OS (median 30.0 vs 7.0 months) among patients whose tumours were KRAS exon 2 wild type compared with those whose tumours harboured KRAS exon 2 mutations. Here, KRAS is linked to neoplasm.